Loading...
The personalized mRNA therapy, called intismeran autogene, combined with Merck's Keytruda significantly boosted recurrence-free and metastasis-free survival in over 1,100 patients with resected stage IIB-IV melanoma. This marks the first Phase 3 success for a neoantigen mRNA cancer vaccine, outperforming Keytruda alone, with companies planning detailed data releases and regulator talks soon.